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ABSTRACT
Background: Pancreatic cancer carries a poor prognosis. To date, there has been little research
devoted to decision-making regarding treatment options in pancreatic cancer, including the rationale
for choosing to withhold tumor targeting treatment (TTT). This study aims to gain insight into the char-
acteristics of patients receiving no TTT, the reasons for this decision and their survival.
Methods: All patients diagnosed in the Netherlands between 1 January 2014 and 30 June 2015 with a
proven pancreatic adenocarcinoma or a pathologically unverified pancreatic tumor were identified in
the Netherlands Cancer Registry. Information on initial management, patient characteristics, main rea-
sons for no TTT (as reported in medical charts) and survival were analyzed.
Results: A total of 3090 patients was included. Of these patients, 1818 (59%) received no TTT. Median
age of no TTT patients was 74 years (range 35–99) versus 66 years (30–87) for TTT patients. In the no
TTT group 77% had a clinical stage III/IV versus 57% of patients who received TTT. Main reasons for
not starting TTT were patient’s choice (27%) and extensive disease (21%). Median survival of patients
who did not receive TTT was 1.9 months, ranging from a median survival of 0.8 months (when main
reason to withhold TTT was short life expectancy) to 4.4 months (main reason to withhold TTT: old
age). In the latter group, a relatively large proportion of clinical stage I tumors was present (37%).
Conclusion: The majority of patients with pancreatic cancer received no TTT and had a very poor
median survival. In most patients, patient’s choice not to start treatment was the main reason for with-
holding treatment, suggesting patient’s involvement in decision-making.
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Introduction
Pancreatic cancer carries a poor prognosis regardless of
stage, with a median survival ranging from three months
when untreated up to 28 months in case of surgical resec-
tion followed by adjuvant chemotherapy [1,2]. The majority
of patients are diagnosed with non-resectable locally
advanced or metastatic disease. For patients with these
advanced stages, unfortunately, just few therapeutic options
are available.
Since most cases of pancreatic cancer are diagnosed in the
absence of curative treatment options, management primarily
focuses on improving survival and quality of life by slowing
disease progression and relieving symptom burden. In these
cases, the main management options are best supportive care
or chemotherapy with palliative intent. For years no substan-
tial progress was made in chemotherapeutic treatment of
advanced pancreatic cancer. Since 2011, however, new che-
motherapeutic regimens have emerged. The FOLFIRINOX regi-
men is currently the most effective with an increase in overall
survival from 6.8–11 months, compared to gemcitabine [3].
However, this treatment is mainly suitable for younger (<76
years) and relatively fit patients, due to its toxicity. Pancreatic
cancer however disproportionately affects elderly individuals;
the mean age at diagnosis is 70 years and almost 40% of
patients are diagnosed after age 75 years [4]. A recent study
that involved more elderly patients (42% 65 years and 10%
75 years) showed that the addition of nab-paclitaxel to gem-
citabine among patients with metastatic pancreatic cancer
improved overall survival from 6.6–8.7 months [5]. For patients
with advanced pancreatic cancer who are not eligible for an
intensive first-line combination chemotherapy regimen, che-
motherapeutic treatment with gemcitabine alone may be an
option. Despite its very limited response rate (6–11%) [6,7]
and marginal survival benefit (5.6 versus 4.4 months in fluo-
rouracil-treated patients), gemcitabine was approved as first-
line regimen because of significant improvement in pain, per-
formance status or weight [8]. Overall, the survival benefit of
chemotherapeutic regimens for advanced pancreatic cancer
unfortunately remains limited.
Clearly, given the limited benefit of therapies, treatment
decision-making in pancreatic cancer can be challenging [9].
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An ultimate decision regarding treatment for pancreatic can-
cer could be to withhold tumor targeting treatment (TTT)
and to decide for best supportive care only.
In order to decide which treatment plan is appropriate for
a patient, it is of utmost importance to weigh patients prefer-
ences and clinical circumstances such as life expectancy,
potential side effects and potential positive effects of treat-
ment on quality and quantity of life. That decision-making is
not a straightforward process and is supported by the influ-
ence of individual preferences and experiences of physicians
on treatment considerations [10] and inter-hospital variation
in the prescription of palliative chemotherapy [11]. Moreover,
patients with pancreatic cancer may perceive barriers in the
shared decision-making process, such as different clinical
opinions of medical experts, a feeling of pressure to accept
treatment and a sense that there are no other treatment
options [12].
Since most studies focus on tumor targeting treatments
for pancreatic cancer, there has been little research devoted
to the treatment decision-making process in pancreatic can-
cer, including the considerations and rationale for choosing
to withhold TTT. There is some information available; how-
ever, these studies focus on subgroups such as octogenarians
[13], patients with early stage [14] or advanced stage disease
[15,16]. One Danish population-based study is available,
which reports different baseline characteristics of treated and
untreated patients with pancreatic cancer (unselected cohort)
in the pre-FOLFIRINOX era [17]. In order to better understand
the decision-making process regarding treatment for all
patients with pancreatic cancer, population-based research
can be of additive value. Therefore, this study aims to gain
insight into the characteristics of patients not receiving TTT
as initial management compared to those receiving TTT, the
reasons for this decision and their survival.
Methods
Data collection
Data of all patients diagnosed with pancreatic cancer
between 1 January 2014 and 30 June 2015 (n¼ 3424) were
obtained from the Netherlands Cancer Registry (NCR). This
nationwide registry collects data on all patients newly diag-
nosed with cancer in the Netherlands and covers nearly 17
million inhabitants. Primary source of notification of the NCR
is the automated nationwide pathological archive (PALGA),
supplemented by additional sources, such as the national
registry of hospital discharge, multidisciplinary team reports
and diagnosis therapy combinations (specific codes for reim-
bursement purposes). Required information on diagnosis, ini-
tial treatment, patient- and tumor characteristics are
routinely extracted after notification in all hospitals in the
Netherlands, by trained registration administrators operating
on behalf of the NCR.
Patient selection
For the present study we selected patients diagnosed with a
proven adenocarcinoma of the pancreas, a not otherwise
specified carcinoma of the pancreas (ICD-O morphology
codes 8010, 8012, 8020, 8140, 8141, 8144, 8260, 8310, 8440,
8480, 8481, 8490, 8500and 8560) [18] or a non-microscopic
verified neoplasm of the pancreas between 1 January 2014
and 30 June 2015.
Measures
Clinical data were obtained from the NCR and include stage,
pathological verification, tumor localization, date of diagnosis,
vital status, use of multidisciplinary team consultation and
initial treatment received. The number of comorbid condi-
tions, including previous malignancies, was assessed in a sub-
sample of the NCR: the area of the previous Eindhoven
Cancer Registry (ECR). Tumors were classified according to
the Tumor Lymph Node Metastases (TNM) classification. In
the present study, the TNM classification seventh edition was
used [19]. Information on vital status of patients was
obtained through linkage with civil municipal registries and
the central bureau for genealogy, which collects data on all
deceased Dutch citizens. Follow-up of vital status was calcu-
lated as the time from the date of diagnosis to the date of
death or to 1 February 2017. In patients with a proven car-
cinoma, date of diagnosis was based on the first date of
cytological or histological confirmation. For patients with a
non-microscopic verified neoplasm of the pancreas, the date
of first inpatient or outpatient presentation was used as day
0. The same definition was used for no TTT and TTT patients.
Survival was calculated based on all-cause mortality.
Reported initial treatments were classified as either tumor
targeting therapy or best supportive care. Tumor targeting
therapies included chemotherapy, both palliative and adju-
vant, surgical tumor resection and other treatments aimed at
primary tumor reduction or destruction, such as radiotherapy,
radiofrequency ablation or irreversible electroporation. Best
supportive care comprised interventions aimed at symptom
burden instead of tumor reduction, including biliary stenting
or bypass, enteral stenting or gastroenterostomy, and pallia-
tive radiotherapy on bone metastases. Cases with no or
incomplete information available on first-line treatment were
excluded (not yet completed at time of patient selection).
The main reason for withholding tumor targeting treat-
ment was extracted from the medical records by the trained
administrators, allowing them to choose one of nine prede-
fined options: comorbidity, functional status, social context,
old age, short life expectancy, patient refusal, extensive dis-
ease, other and unknown. Since ‘social context’ was used
only once, this category was recoded into ‘other’.
Furthermore, additional notes in the registry were screened
to identify incomplete information on treatment and main
reason for withholding tumor targeting treatment.
In order to ensure the reliability and representativeness of
the main reason for withholding tumor targeting treatment,
an experienced researcher (NR) and medical oncologist in
training (MZ) conducted a sample in one hospital by per-
forming a medical chart review of 26 evaluable cases. In 85%
of the cases, the opinion of the researcher and medical
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oncologist in training was similar to the opinion of the
trained administrator.
Socio-demographic data of the patients were also
obtained from the NCR. Socio-demographic variables
included age at diagnosis, gender and socio-economic status
(SES). SES was based on four-digit postal code of the resi-
dence area of the patient, combining aggregated individual
fiscal data on the economic value of the home and house-
hold incomes and was categorized into low, medium or
high [20].
Statistical analyses
Descriptive analyses were used to analyze patient and
tumor characteristics, initial treatment characteristics and
main reasons for no TTT (as reported in medical charts).
Characteristics of patients receiving no TTT or TTT were com-
pared using t-test (continuous variables) and Chi2-test (cat-
egorical variables). Two-sided p values of<.01 were
considered statistically significant. Median survival was calcu-
lated and survival curves were constructed by the Kaplan-
Meier method, followed by a log rank test. Statistical analyses
were performed with STATA Statistical Software (release 14.1,
StataCorp, College Station, TX).
Results
Between 1 January 2014 and 30 June 2015, 3424 patients
were diagnosed with pancreatic cancer in the Netherlands, of
whom 3314 were diagnosed with a proven adenocarcinoma,
a not otherwise specified carcinoma or a non-microscopic
verified neoplasm of the pancreas. Two hundred twenty-four
(7%) patients were excluded from analysis because no or
incomplete information on initial treatment was available,
resulting in 3090 selected patients for analysis.
Patient characteristics
The median age at diagnosis was 70 years (range 30–99
years), 51% were male and 56% had metastases at time of
diagnosis (Table 1). One thousand eight hundred eighteen
patients (59%) received no TTT and 41% received TTT
(n¼ 1272), 40% of whom underwent surgical resection, 56%
received chemotherapy with palliative intent and 4%
received other treatments aimed at primary tumor reduction
or destruction. Median age of patients receiving no TTT was
74 years (range 35–99 years) versus 66 years (range 30–87
years) for patients who received TTT (p< .001). In the no TTT
group, 77% had a clinical stage III/IV, whereas this was the
case in 57% of patients who received TTT (p< .001). Overall,
socioeconomic status differed between the no TTT group in
comparison to the TTT group, respectively. Thirty two versus
27% had a low SES (p¼ .002). More patients who did not
receive TTT had at least two comorbid conditions compared
to the patients who received TTT (52 versus 35%, p¼ .002).
Reasons for deciding to start best supportive care
In 84% of patients, the reason for not starting TTT was
recorded. Main reasons for not starting TTT were patient’s
choice to withhold treatment (27%) and extensive disease
(21%; Table 2). Patients who chose to withhold treatment
had mainly stage IV disease (65%), median age was 72 years
and SES was equally distributed among low (29%), middle




No tumor targeting treatment
n¼ 1818
Tumor targeting treatment
n¼ 1272 p value
Age, median (range) 70 (30–99) 74 (35–99) 66 (30–87) .000
Sex, n (%) .024
Male 1584 (51%) 901 (50%) 683 (54%)
Female 1506 (49%) 917 (50%) 589 (46%)
Tumor location, n (%)
Head 1697 (55%) 973 (54%) 724 (57%) .062
Corpus 390 (13%) 237 (13%) 153 (12%) .406
Tail 541 (18%) 331 (18%) 210 (17%) .222
Other/unknown 462 (15%) 277 (15%) 185 (15%) .595
Pathological verification, n (%) 2320 (75%) 1105 (61%) 1215 (96%) .000
Socioeconomic status, n (%) .008
Low 928 (30%) 584 (32%) 343 (27%)
Medium 1235 (40%) 710 (39%) 525 (41%)
High 927 (30%) 524 (29%) 404 (32%)
Multidisciplinary team consultation, n (%) 2062 (67%) 1012 (56%) 1050 (83%) .000
Surgical exploration not followed by resection, n (%) 230 (7.4%) 127 (7.0%) 103 (8.1%) .247
Clinical stage, n (%)
I 381 (12%) 166 (9.1%) 215 (17%) .000
II 407 (13%) 179 (9.8%) 228 (18%) .000
III 382 (12%) 206 (11%) 176 (14%) .037
IV 1744 (56%) 1191 (66%) 553 (43%) .000
Unknown 176 (5.7%) 76 (4.2%) 100 (7.9%) .000
Number of comorbid conditionsa n¼ 454 n¼ 273 n¼ 181 .002
0 69 (15%) 35 (13%) 34 (19%)
1 111 (24%) 65 (24%) 46 (25%)
2 or more 205 (45%) 141 (52%) 64 (35%)
Unknown 69 (15%) 32 (12%) 37 (20%)
aThe number of comorbid conditions was assessed in a subsample of the Netherlands Cancer Registry (NCR): the area of the previous Eindhoven Cancer
Registry (ECR).
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(41%) and high (30%) scores. In 8.9% of patients, “other than
the predefined reasons’ was indicated. Additional notes in
the registry showed that in these cases, the following other
reasons were mainly reported: more than one reason applic-
able, early or premature death which made it impossible to
have started initial treatment at all and the physician’s
assessment that treatment had no or too little benefit on
quality and quantity of life. In patients with old age as main
reason to withhold TTT (n¼ 41, 2.3%, median age 86, range
77–92 years), 37% of the patients had a clinical stage I tumor,
compared with 1–20% in patients with other reasons for no
TTT. These patients were less often discussed in a multidis-
ciplinary team consultation, 37 versus 56% in patients with
other reasons for no TTT (p¼ .013).
Survival of patients with pancreatic cancer
Median survival of patients who received no TTT was 1.9
months, ranging from a median survival of 0.8 months (when
the main reason to withhold TTT was short life expectancy)
to 4.4 months (main reason to withhold TTT: old age;
Figure 1). In the TTT group, median overall survival was 10.6
months. Patients who underwent surgical resection had a
median survival of 19.4 months; patients treated with pallia-
tive chemotherapy had a median survival of 6.9 months (all
stages). Survival curves of patients receiving TTT or no TTT
for different reasons differed significantly (p< .001). The
superior median survival of patients who received TTT was
similar in both younger and older patients; 10.2 months in
patients up to 70 years and 11 months in patients in patients
aged 70 years and above (p¼ .533) versus 1.8 and 2 months,
respectively in patients who received no TTT (although sur-
vival curves of patients with no TTT appeared similar, they
differed significantly, p¼ .006; Figure 2). This was also
observed in a subgroup analysis among only stage IV
patients (data not shown).
Discussion
This population-based study among 3090 patients with pan-
creatic adenocarcinoma or a pathologically unverified pancre-
atic tumor in the Netherlands showed that the majority
(59%) of patients received no tumor targeting treatment,
whereas 41% received tumor targeting treatment. The most
prevalent reasons for choosing no TTT were patient’s choice
to withhold treatment and extensive disease. Median survival
of patients who received no TTT was very poor, 1.9 versus
10.6 months in patients receiving TTT.
Little information is known regarding the tumor targeting
treatment rate in the pancreatic cancer population.
Population-based data from Ireland from 1994 to 2003
showed that 80% of patients received no TTT. During the
Table 2. Characteristics of patients with pancreatic cancer in the Netherlands receiving no tumor targeting treatment (n¼ 1818) according to reasons for
this decision.
Patient’s choice Extensive disease Functional status Short life expectancy Comorbidity Old age Other Unknown
n¼ 492 (27%) n¼ 381 (21%) n¼ 280 (15%) n¼ 105 (5.8%) n¼ 60 (3.3%) n¼ 41 (2.3%) n¼ 162 (8.9%) n¼ 297 (16%)
Age, median (range) 72 (40–96) 74 (38–99) 74 (39–94) 71 (41–91) 77 (52–91) 86 (77–92) 74 (45 –94) 77 (35–98)
Socioeconomic status
Low 29% 31% 37% 25% 37% 37% 29% 36%
Medium 41% 41% 36% 46% 45% 24% 43% 33%
High 30% 28% 27% 29% 18% 39% 28% 30%
MDT consultation 64% 50% 54% 48% 52% 37% 61% 55%
Clinical stage
I 9.6% 1.1% 13% 1.0% 20% 37% 8.0% 13%
II 8.7% 5.5% 7.9% 10% 18% 15% 10% 16%
III 13% 14% 6.4% 4.8% 8.3% 9.8% 9.9% 14%
IV 65% 78% 67% 84% 42% 29% 70% 49%





































No tumor targeting treatmentTumor targeting treatment
Figure 1. Overall survival of patients with pancreatic cancer, subdivided by tumor targeting treatment versus no tumor targeting treatment and reasons to with-
hold treatment.
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course of this time period, the proportion of patients receiv-
ing no TTT decreased considerably [21]. A more recent
Danish population-based study from 2007 to 2009 showed
that 56% of the patients with pancreatic cancer did not
receive TTT, which is similar to our data [17]. However, US
data from 2008 to 2012 based on three large integrated
claim databases showed an even lower proportion of
patients with pancreatic cancer receiving no treatment
(35–55%) [22]. This may be an underestimation of the pro-
portion of untreated patients as claim databases only reflect
the insured (cancer) population or could be related to cul-
tural differences when it comes to deciding not to treat the
tumor. The reported median overall survival of patients with
pancreatic cancer who did not receive TTT in our study was
1.9 months, slightly longer than population-based data from
Denmark (1.1 months) [17]. In comparison, the median sur-
vival of selected patients from the first randomized trials that
received best supportive care only was 2–4 months [23–25].
Our analyses demonstrated various reasons for withhold-
ing tumor targeting treatment. Patient’s choice was the most
prevalent reason (27%). Although older age appears to
increase the preference for a more passive role in the deci-
sion-making process [26], our results are in line with the pre-
viously reported percentage of octogenarians who chose to
withhold treatment (29%) [13]. The fact that a large propor-
tion of patients decided to withhold treatment could indicate
that they play a role in the decision-making process. The
value of shared decision-making is widely embraced as it is
considered essential for appropriate care and may have a
beneficial impact on quality of life [27]. Results of a German
qualitative interview study demonstrate that the involvement
of patients in the decision-making process may even increase
further during the course of their illness, due to increasing
experience with the disease and treatment [28]. However,
overall the involvement of patients in the decision-making
process remains limited [29,30].
Some previous studies, assessing different pancreatic can-
cer populations (non-metastatic pancreatic cancer, stage I
pancreatic adenocarcinoma and advanced pancreatic cancer),
have also investigated reasons and predictors for withholding
tumor targeting treatment. Reasons to withhold treatment
found in these studies are similar to the reasons demon-
strated in our study and include comorbidity [14], unfavor-
able prognosis [31], limited survival gain [31] and old age
[14,32]. However, since these studies focus on subgroups of
patients with pancreatic cancer, comparison with our results
is difficult.
Furthermore, SES may play a role in the decision-making
process, as our data suggest that patients with a higher SES
may be more likely to receive tumor targeting treatment,
which is consistent with several prior studies [11,33]. Patients
with a higher SES are more likely to prefer an active role in
the decision-making process [26] and moreover, a lower SES
is associated with a higher prevalence of comorbidity [34],
which may be a reason for withholding TTT. However, assess-
ment of SES is challenging. In our study SES has been based
on the four-digit postal code of the residence area of the
patient, combining aggregated individual fiscal data on the
economic value of the home and household incomes. This is
a widely used method, although it is a rather crude proxy of
SES and should be interpreted with care. In line, our results
showed that patients who received no TTT, more often had
two or more comorbid conditions.
In patients with old age as main reason to withhold tumor
targeting treatment (2.3%), survival was relatively favorable
compared to patients for whom other main reasons to with-
hold tumor targeting treatment were identified. A rather
large proportion of low stage tumors in this group most
likely explains this. Furthermore, among this group, a large
proportion concerned a pathologically unverified tumor
(76%), what may have led to longer survival due to misclassi-
fication [35]. In addition, older patients receiving tumor tar-
geting treatment seem to have similar survival benefit as
younger patients. This supports current international guide-
lines in which the general consensus states that, advanced
age per se should not be a contraindication for any treat-
ment modality in pancreatic cancer [36]. It remains interest-
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Figure 2. Overall survival of patients with pancreatic cancer, subdivided by tumor targeting treatment versus no tumor targeting treatment and age.
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to withhold tumor targeting treatment, especially in light of
ageism. Nevertheless, one can imagine that there is some
restraint regarding the treatment of older patients due to
their increased frailty. Furthermore, evidence-based data
regarding treatments of these older patients are scarce, due
to under-representation of older adults in cancer registra-
tion trials.
Although there is a general trend towards more aggres-
sive cancer care near the end of life [37], there appears to be
restraint regarding tumor targeting treatment in pancreatic
cancer. This may be related to the pessimistic attitude of
both doctors and patients towards diagnosis and prognosis.
The awareness of the extremely poor prognosis is high
among clinicians [38] and this awareness of the often pallia-
tive nature of the diagnosis is also reflected in the fact that
patients with pancreatic cancer have a higher probability to
be admitted to specialized palliative care units, compared to
other cancer diagnoses, regardless of symptom burden [39].
Strengths and limitations
An important strength of the current study is that we
included a large nationwide population-based sample of pan-
creatic cancer patients. At this population-based level we
were able to investigate characteristics of patients receiving
no tumor targeting treatment and reasons for this decision,
providing valuable information to improve insight into the
decision-making process.
A limitation of our analysis may lie in the assessment of
the reason to withhold treatment. First, this assessment may
be susceptible to interpretation due to interrelatedness of
several reasons to start or withhold treatment. However, the
item was registered by experienced and trained administra-
tors and subject to strict quality control. Furthermore, the
performed medical chart review of a sample in one hospital
suggests that it is a reliable measure. The 15% differences in
reasons for withholding treatment was mainly related to
interrelatedness of reasons, such as short life expectancy and
extensive disease. Finally, in our database, only one main rea-
son to withhold TTT was registered, while in real life often a
combination of various reasons may play a role in the deci-
sion-making process. Moreover, medical records often con-
tain a limited reflection (from a doctors perspective only) of
what is actually considered and discussed in consulting
rooms or multidisciplinary team consultations. In addition,
information regarding certain clinical parameters that may be
valuable in the decision-making process is missing, such as
performance status, surgical resectability and partly,
comorbidity.
The proportion of patients not receiving TTT in particular
could be underestimated in the NCR, since among unregis-
tered patients pathological confirmation is lower and survival
is significantly poorer, as was demonstrated in a recent
Dutch study [40]. It is plausible that in these patients it was
decided to abstain from pathological confirmation and TTT,
because of poor clinical condition or poor prognosis.
Practical implications
Our results show that there is restraint regarding tumor tar-
geting treatment of pancreatic cancer, a decision that may
be understandable when in view of quality of life, disadvan-
tages of treatment may outweigh its benefits. Our study,
however, is not focused on the quality of life of patients who
do not receive tumor targeting treatment versus patients
who receive tumor targeting treatment. Assessing quality of
life by using patient reported outcome measures (PROMs) is
seen as an increasingly important aspect in determining
appropriate oncological care [41]. Hence, PROMs are now
recorded in three comprehensive nationwide cohorts of pan-
creatic, esophageal/gastric and colorectal cancer patients in
the Netherlands [42]. Our study provides scope for future
research into quality of life to further improve decision-mak-
ing processes regarding treatment of patients with pancreatic
cancer.
Conclusion
The majority of patients with pancreatic cancer received no
TTT and had a very poor median survival. In most patients,
patient’s choice not to start treatment was the main docu-
mented reason for withholding treatment, suggesting
patient’s involvement in decision-making.
Disclosure statement
No potential conflict of interest was reported by the authors.
References
[1] Royal R. Cancer of the pancreas. Cancer principles and practice of
oncology. Vol. 9. Philadelphia: Lippincott William & Wilkins; 2011.
[2] Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adju-
vant gemcitabine and capecitabine with gemcitabine monother-
apy in patients with resected pancreatic cancer (ESPAC-4): a
multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;
389:1011–1024.
[3] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemci-
tabine for metastatic pancreatic cancer. N Engl J Med. 2011;
364:1817–1825.
[4] SEER Cancer Statistics Review, 1975-2014. [Internet]. Bethesda:
National Cancer Institute; [based on November 2016 SEER data
submission, posted to the SEER web site, April 2017]. Available
from: https://seer.cancer.gov/csr/1975_2014/
[5] Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus
gemcitabine for metastatic pancreatic cancer: long-term survival
from a phase III trial. J Natl Cancer Inst. 2015;107. DOI:10.1093/
jnci/dju413
[6] Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcita-
bine in patients with advanced pancreatic cancer. Br J Cancer.
1996;73:101–105.
[7] Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcita-
bine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma
of the pancreas. Invest New Drugs. 1994;12:29–34.
[8] Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in sur-
vival and clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: a randomized trial.
J Clin Oncol. 1997;15:2403–2413.
[9] Clarke G, Johnston S, Corrie P, et al. Withdrawal of anticancer
therapy in advanced disease: a systematic literature review. BMC
Cancer. 2015;15:892.
6 M. ZIJLSTRA ET AL.
[10] Schildmann J, Tan J, Salloch S, et al. “Well, I think there is great
variation…”: a qualitative study of oncologists' experiences and
views regarding medical criteria and other factors relevant to
treatment decisions in advanced cancer. Oncologist. 2013;18:
90–96.
[11] Bernards N, Haj Mohammad N, Creemers GJ, et al. Ten weeks to
live: a population-based study on treatment and survival of
patients with metastatic pancreatic cancer in the south of the
Netherlands. Acta Oncologica. 2015;54:403–410.
[12] Ziebland S, Chapple A, Evans J. Barriers to shared decisions in the
most serious of cancers: a qualitative study of patients with pan-
creatic cancer treated in the UK. Health Expect. 2015;18:
3302–3312.
[13] King JC, Zenati M, Steve J, et al. Deviations from expected treat-
ment of pancreatic cancer in octogenarians: analysis of patient
and surgeon factors. Ann Surg Oncol. 2016;23:4149–4155.
[14] Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to
operate on early stage pancreatic cancer. Ann Surg. 2007;
246:173–180.
[15] Kao S, Shafiq J, Vardy J, et al. Use of chemotherapy at end of life
in oncology patients. Ann Oncol. 2009;20:1555–1559.
[16] Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally
advanced pancreatic cancer in the real world: population-based
practices and effectiveness. J Clin Oncol. 2003;21:3409–3414.
[17] Bjerregaard JK, Mortensen MB, Schonnemann KR, et al.
Characteristics, therapy and outcome in an unselected and pro-
spectively registered cohort of pancreatic cancer patients. Eur J
Cancer. 2013;49:98–105.
[18] Fritz AP, C. Jack A. International classification of diseases for
oncology. 3rd ed. Geneva: World Health Organisation; 2000.
[19] Sobin LH. TNM classification of malignant tumors, 7th ed. Oxford:
Wiley-Blackwell; 2009.
[20] Duijn CK, I. Sociaal-economische status indicator op postcode
niveau [Socio-economic status indicator at postcode level].
Maandstat Bevolking Volksgezond. 2002;50:32–35. Dutch.
[21] Sharp L, Carsin AE, Cronin-Fenton DP, et al. Is there under-treat-
ment of pancreatic cancer? Evidence from a population-based
study in Ireland. Eur J Cancer. 2009;45:1450–1459.
[22] Seal B, Xia F, Germino R, et al. An evaluation of national treat-
ment trends in pancreatic cancer. J Clin Oncol.
2014;32(Suppl 15):e15211.
[23] Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves
survival and quality of life in advanced pancreatic and biliary can-
cer. Ann Oncol. 1996;7:593–600.
[24] Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pan-
creatic cancer: results of a controlled, prospective, randomised,
multicentre trial. BMJ. 1980;281:1589–1591.
[25] Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs sur-
vival in inoperable pancreatic carcinoma. Br J Surg. 1994;81:
882–885.
[26] Tariman JD, Berry DL, Cochrane B, et al. Physician, patient, and
contextual factors affecting treatment decisions in older adults
with cancer and models of decision making: a literature review.
Oncol Nurs Forum. 2012;39:E70–E83.
[27] Kashaf MS, McGill E. Does shared decision making in cancer treat-
ment improve quality of life? A systematic literature review. Med
Decis Making. 2015;35:1037–1048.
[28] Schildmann J, Ritter P, Salloch S, et al. 'One also needs a bit of
trust in the doctor … ': a qualitative interview study with pancre-
atic cancer patients about their perceptions and views on infor-
mation and treatment decision-making. Ann Oncol.
2013;24:2444–2449.
[29] Tariman JD, Berry DL, Cochrane B, et al. Preferred and actual par-
ticipation roles during health care decision making in persons
with cancer: a systematic review. Ann Oncol. 2010;21:1145–1151.
[30] Brom L, De Snoo-Trimp JC, Onwuteaka-Philipsen BD, et al.
Challenges in shared decision making in advanced cancer care: a
qualitative longitudinal observational and interview study. Health
Expect. 2017;20:69–84.
[31] Buiting HM, Brink M, Wijnhoven MN, et al. Doctors' reports about
palliative systemic treatment: a medical record study. Palliat Med.
2017;31:239–246.
[32] Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and
outcome of pancreatic cancer in the United States. Ann Surg
Oncol. 2007;14:1320–1326.
[33] van Roest MH, van der Aa MA, van der Geest LG, et al. The
impact of socioeconomic status, surgical resection and type of
hospital on survival in patients with pancreatic cancer. A popula-
tion-based study in the Netherlands. PloS One. 2016;11:e0166449.
[34] Louwman WJ, Aarts MJ, Houterman S, et al. A 50% higher preva-
lence of life-shortening chronic conditions among cancer patients
with low socioeconomic status. Br J Cancer. 2010;103:1742–1748.
[35] Zijlstra M, Bernards N, de Hingh IH, et al. Does long-term survival
exist in pancreatic adenocarcinoma? Acta Oncologica. 2016;
55:259–264.
[36] Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas:
ESMO Clinical Practice Guidelines for diagnosis, treatment and fol-
low-up. Ann Oncol. 2015;26: v56–v68.
[37] Ho TH, Barbera L, Saskin R, et al. Trends in the aggressiveness of
end-of-life cancer care in the universal health care system of
Ontario, Canada. J Clin Oncol. 2011;29:1587–1591.
[38] Klapdor R. Perspectives in chemotherapy of pancreatic cancer.
Eur J Surg Oncol. 1991;17:153–166.
[39] Adsersen M, Thygesen LC, Jensen AB, et al. Is admittance to spe-
cialised palliative care among cancer patients related to sex, age
and cancer diagnosis? A nation-wide study from the Danish
Palliative Care Database (DPD). BMC Palliat Care. 2017;16:21.
[40] Fest J, Ruiter R, van Rooij FJ, et al. Underestimation of pancreatic
cancer in the national cancer registry - reconsidering the inci-
dence and survival rates. Eur J Cancer. 2017;72:186–191.
[41] Kotronoulas G, Kearney N, Maguire R, et al. What is the value of
the routine use of patient-reported outcome measures toward
improvement of patient outcomes, processes of care, and health
service outcomes in cancer care? A systematic review of con-
trolled trials. J Clin Oncol. 2014;32:1480–1501.
[42] Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, et al.
Nationwide comprehensive gastro-intestinal cancer cohorts: the
3P initiative. Acta Oncologica. 2018;57:195–202.
ACTA ONCOLOGICA 7
